KeyBanc Capital Markets initiated coverage of Allscripts Healthcare with a rating of Sector Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/19/2024 | $15.00 → $10.00 | Buy → Hold | Deutsche Bank |
| 1/3/2024 | $11.00 | Equal Weight | Barclays |
| 7/6/2023 | Buy → Hold | Argus | |
| 4/12/2023 | $13.00 | Equal-Weight | Stephens |
| 2/1/2023 | $17.00 → $18.50 | Overweight → Neutral | Piper Sandler |
| 12/7/2022 | $26.00 | Hold → Buy | Argus |
| 11/9/2022 | $22.00 → $23.00 | Neutral → Buy | Goldman |
| 11/4/2022 | $17.00 | Overweight | Piper Sandler |
Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that it filed its comprehensive Annual Report on Form 10-K for the year ended December 31, 2022, which also contains certain restated financial statements for periods in fiscal year 2022, 2021 and 2020 (the "2022 Form 10-K"), with the Securities and Exchange Commission ("SEC"). "This filing represents an important step toward regaining compliance with our financial reporting obligations," said Tom Langan, Interim Chief Executive Officer of Veradigm. "We remain focused on remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we
Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go
Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve
NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
3 - Veradigm Inc. (0001124804) (Issuer)
3 - Veradigm Inc. (0001124804) (Issuer)
3 - Veradigm Inc. (0001124804) (Issuer)
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we
Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti
Veradigm®, Inc. (NASDAQ:MDRX), will report its financial results for the three and twelve months ended December 31, 2022 after the close of the regular stock market hours on Wednesday, March 1, 2023. Veradigm management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Fourth-Quarter 2022 Financial Results Call Details To listen to the conference call, participants may log onto the Veradigm Investor Relations website. Participants also may access the conference call by dialing 877-269-7756 or 201-689-7817 and requesting Conference ID # 13735356. A replay of the call will be available for a period of a year on the Veradi
4/A - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously
Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00
Argus downgraded Veradigm from Buy to Hold
8-K - Veradigm Inc. (0001124804) (Filer)
8-K/A - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)